Previous 10 | Next 10 |
JP Morgan has downgraded Kala Pharmaceuticals (NASDAQ:KALA) to underweight from neutral as the firm said that sales of the dry eye treatment Eysuvis (loteprednol etabonate) were below expectations. The firm cut its sales expectations in fiscal year 2022 for the eye drops as follows: Q1, $1.9M...
Kala Pharmaceuticals, Inc. (KALA) Q4 2021 Earnings Conference Call March 29, 2022 08:00 ET Company Participants Jill Steier - Executive Director, Investor Relations and Corporate Communications Mark Iwicki - Chairman and Chief Executive Officer Todd Bazemore - President and Chief Operating Of...
Kala Pharmaceuticals (KALA -13.4%) stock following its Q4 results, which missed to beat analysts' estimates. Q4 net revenues decreased -17.07% Y/Y to ~$1.9M. The total consisted of $1.2M from EYSUVIS and $0.7M from INVELTYS. The company said EYSUVIS net revenue increased by $0.9M in Q4 ...
Gainers: IGM Biosciences IGMS +37%. TRxADE HEALTH MEDS +21%. Ginkgo Bioworks DNA +14%. NexImmune NEXI +13%. BioSig Technologies (BSGM) +8%. Losers: NeoGenomics NEO -34%. Progenity PROG -25%. Aveanna Healthcare (AVAH) -21%. Kala Pharmaceuticals...
NeoGenomics (NEO) -29% on Q1 guidance cut; CEO to quit Progenity (PROG) -22% on Q4 earnings release. Stryve Foods (SNAX) -21% releases inaugural shareholder report. Kala Pharmaceuticals (KALA) -19% on Q4 earnings release. Lipocine (LPCN) -15% its partne...
Kala Pharmaceuticals press release (NASDAQ:KALA): Q4 GAAP EPS of -$0.68 misses by $0.29. Revenue of $1.86M (-17% Y/Y) misses by $1.55M. As of December 31, 2021, cash and cash equivalents of $92.1 million, compared to $124.5 million of cash, cash equivalents and short-term investments as of Se...
-- Achieved $11.2 Million in Net Revenue in 2021 -- -- Expanded Coverage for EYSUVIS ® to 118 Million Commercial Lives and 7.1 Million Medicare Lives -- -- KPI-012 Phase 1b Clinical Data Accepted for Presentation at ARVO; Initiation of Phase 2/3 Clinical Trial of KPI-...
ASO, BGRY, CONN, DPRO, EH, ESLT, HUMA, KALA, LODE, LOVE, MKC, SCYX, UXIN For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
OKYO Pharma is a UK based developer of next generation ocular therapeutics based on GPCR and MRGPR. The company plans direct Phase 2 trial of its lead candidate following a pre-IND meeting with FDA. The company has filed F-1 for an IPO of its ADSs. For further details see: ...
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...